Last Price$19.1(7.5%)
Market Cap$14.6B
LTM Total Liabilities
$46.8M
YoY Growth
-62.6%
3Y CAGR
+15.9%
5Y CAGR
+34.3%
Stock quality & Intrinsic value
6/10
97.4% overvalued
Summit Therapeutics Inc. Total Liabilities
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Liabilities | $4,430.6K | $12.4M | $30.4M | $11.3M | $8,237.4K | $3,580.9K | $3,687.8K | $3,821.8K | $5,066.5K | $10.0M | $7,998.1K | $64.6M | $88.5M | $29.6M | $19.0M | $23.0M | $30.1M | $537.5M | $125.3M | $46.8M |
Overvalued or undervalued?
Check the intrinsic value for SMMT
and see if it's the right time to invest.
Summit Therapeutics Inc. (SMMT) Total Liabilities comparison analysis
General
LTM Total Liabilities
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Summit Therapeutics Inc.SMMT
$46.8M
(62.6%)
15.9%
42.0%
Median Peer Set
$3,228.7M
22.0%
5.1%
20.8%
Novo Nordisk A/SNVO
$44.6B
44.9%
37.6%
36.5%
Royalty Pharma plcRPRX
$7,880.0M
25.1%
2.7%
4.5%
Vertex Pharmaceuticals IncorporatedVRTX
$6,123.6M
18.9%
22.5%
22.4%
Alnylam Pharmaceuticals, Inc.ALNY
$4,172.9M
3.0%
11.0%
34.3%
BioNTech SEBNTX
$3,659.6M
47.9%
(15.9%)
59.1%
Regeneron Pharmaceuticals, Inc.REGN
$2,797.8M
(60.6%)
(25.1%)
(5.5%)
BeiGene, Ltd.BGNE
$2,394.8M
35.9%
7.5%
32.5%
Incyte CorporationINCY
$1,996.7M
25.4%
19.7%
19.2%
United Therapeutics CorporationUTHR
$920.0M
(22.2%)
(8.7%)
(4.1%)
argenx SEARGX
N/A
N/A
N/A
N/A
SMMT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1.7 338.9% | 3.8 119.8% | 12.1 219.9% | 0.5 (96.0%) | 0.5 (1.1%) | 1.9 290.6% | 4.4 138.3% | 4.6 2.5% | 3.6 (21.8%) | 3.7 4.3% | 0.0 (100.0%) | 3.9 0.0% | 46.8 1,114.8% | 74.9 59.9% | 0.8 (98.9%) | 0.9 6.6% | 1.8 110.3% | 0.7 (61.1%) | 0.0 (100.0%) | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.8 | 1.1 | 5.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 2.5 | 2.1 | 15.0 |
% margin | 1.0 56.1% | 2.7 70.6% | 7.0 58.3% | 0.5 97.8% | 0.5 100.0% | 1.9 100.0% | 2.8 63.7% | 4.6 100.0% | 3.6 100.0% | 3.7 100.0% | 0.0 0.0% | 3.9 100.0% | 46.7 99.7% | 74.8 100.0% | 0.6 75.4% | 0.9 100.0% | 1.8 100.0% | (1.8) (257.0%) | (2.1) 0.0% | (15.0) 0.0% |
| Operating Expenses | 6.8 | 18.6 | 53.9 | 27.9 | 15.0 | 8.6 | 11.9 | 13.5 | 20.9 | 31.6 | 44.8 | 45.4 | 70.4 | 63.3 | 53.6 | 53.2 | 88.0 | 64.3 | 87.7 | 211.3 |
| Research & Development Expenses (R&D) | 3.3 | 10.8 | 30.7 | 13.3 | 5.8 | 5.7 | 7.7 | 9.1 | 17.0 | 25.6 | 36.4 | 31.7 | 53.4 | 68.2 | 41.7 | 53.3 | 85.4 | 52.0 | 59.5 | 150.8 |
| Selling, General & Administrative Expenses (SG&A) | 3.2 | 3.5 | 14.6 | 9.1 | 6.6 | 4.1 | 3.7 | 4.4 | 5.1 | 11.1 | 11.3 | 13.8 | 22.1 | 21.5 | 11.9 | 19.2 | 23.6 | 26.7 | 28.2 | 60.5 |
% margin | (5.8) (338.9%) | (16.0) (423.8%) | (46.9) (388.4%) | (34.7) (7,198.9%) | (14.5) (3,047.6%) | (14.5) (777.1%) | (7.6) (170.1%) | (11.5) (252.3%) | (17.4) (487.9%) | (31.3) (844.4%) | (43.7) 0.0% | (41.6) (1,078.7%) | (23.7) (50.7%) | 16.4 21.9% | (54.6) (6,766.4%) | (53.2) (6,185.2%) | (86.2) (4,764.3%) | (72.1) (10,235.6%) | (89.7) 0.0% | 0.3 0.0% |
| Interest Income | 1.9 | 3.2 | 3.1 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 4.9 | 0.0 | 0.0 | 0.2 | 1.5 | 10.4 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 1.4 | 2.1 | 0.7 | 0.0 | 0.3 | 0.3 | 4.4 | 16.5 | (8.7) |
| Pre-tax Income | (3.9) | (12.8) | (43.9) | (34.2) | (14.7) | (14.4) | (7.5) | (11.5) | (17.3) | (31.2) | (43.7) | (43.0) | (20.1) | 8.8 | (36.3) | (52.9) | (88.6) | (78.8) | (615.9) | (221.3) |
% effective tax rate | (0.5) 12.8% | (1.8) 13.9% | (3.6) 8.3% | (4.6) 13.3% | (0.9) 6.4% | (3.0) 20.7% | (0.8) 10.1% | (0.9) 7.5% | (1.6) 9.1% | (3.2) 10.2% | (6.6) 15.2% | (7.3) 16.9% | (6.9) 34.5% | (4.3) (49.6%) | (5.8) 15.9% | (0.2) 0.4% | (2.5) 2.8% | (4.4) 5.6% | (0.9) 0.2% | 0.0 0.0% |
% margin | (3.4) (199.7%) | (11.0) (292.1%) | (40.3) (334.1%) | (58.4) (12,109.8%) | (13.7) (2,867.2%) | (11.4) (614.7%) | (6.8) (152.6%) | (10.6) (232.9%) | (15.8) (443.1%) | (28.0) (754.9%) | (37.0) 0.0% | (35.7) (927.6%) | (13.1) (28.1%) | 13.1 17.5% | (30.5) (3,779.1%) | (52.7) (6,127.6%) | (86.1) (4,762.1%) | (74.4) (10,561.1%) | (614.9) 0.0% | (221.3) 0.0% |
| EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.21) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
| Diluted EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.20) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
% margin | (5.4) (313.6%) | (11.4) (302.4%) | (37.2) (308.4%) | (29.0) (6,010.3%) | (8.5) (1,790.5%) | (13.3) (716.0%) | (7.1) (159.0%) | (8.7) (191.3%) | (17.3) (486.0%) | (20.0) (537.9%) | (30.9) 0.0% | (41.5) (1,075.8%) | (41.9) (89.5%) | 15.5 20.7% | (21.4) (2,657.4%) | (37.1) (4,317.9%) | (62.7) (3,468.0%) | (52.6) (7,472.8%) | 1.0 0.0% | 0.3 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Summit Therapeutics Inc.'s Total Liabilities?
As of today, Summit Therapeutics Inc.'s last 12-month Total Liabilities is $46.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Summit Therapeutics Inc.'s Total Liabilities growth rate?
Over the last year, Summit Therapeutics Inc.'s Total Liabilities growth was (62.6%). The average annual Total Liabilities growth rates for Summit Therapeutics Inc. have been 21.5% over the past three years, 34.3% over the past five years.
3) Is Summit Therapeutics Inc.'s Total Liabilities growth rate Good?
Over the last year, Summit Therapeutics Inc.'s Total Liabilities growth was (62.6%), which is lower than industry growth of 0.1%. It indicates that Summit Therapeutics Inc.'s Total Liabilities growth is Bad.